All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

abametapir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	5403	1762-34-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: abametapir xeglyze Ha44	Abametapir is a metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice. Molecular weight: 184.24 Formula: C12H12N2 CLOGP: 2.56 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 25.78 ALOGS: -2.27 ROTB: 1 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.595		Moderate	0.70
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.767		Moderate	0.70
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	97.275	10^-6 cm/s	Moderate	0.70
dh-clint	Dog hepatocyte intrinsic clearance	304.789	uL/min/10^6 cells	Moderate	0.70
dppb	Dog plasma protein binding (% unbound)	19.560	%	Moderate	0.70
fcs-ppb	Fetal calf serum protein binding (% unbound)	31.420	%	Moderate	0.70
herg	hERG pIC50	4.446	pIC50	Moderate	0.70
hh-clint	Human hepatocyte intrinsic clearance	201.837	uL/min/10^6 cells	Moderate	0.70
hlm-clint	Human liver microsomal intrinsic clearance	680.769	uL/min/mg protein	Moderate	0.70
hppb	Human plasma protein binding (% unbound)	10.750	%	Moderate	0.70
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,MARK4,PDK4,PRKDC,SIK2,SIK3,STK33,TEK	24
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.310		Moderate	0.70
mh-clint	Mouse hepatocyte intrinsic clearance	887.156		Moderate	0.70
mppb	Mouse plasma protein binding (% unbound)	13.090		Moderate	0.70
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.075		Moderate	0.70
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	26.010	%	Moderate	0.70
rh-clint	Rat hepatocyte intrinsic clearance	236.048	uL/min/10^6 cells	Moderate	0.70
rh-fuinc	Rat hepatocyte fraction unbound in incubation	93.170	%	Moderate	0.70
rppb	Rat plasma protein binding (% unbound)	13.380	%	Moderate	0.70
solubility-dd	Solubility at pH 7.4 in DMSO	193.197	uM	Moderate	0.70

Approvals:

Date	Agency	Company	Orphan
July 24, 2020	FDA	DR REDDYS LABS SA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P03AX07	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Other ectoparasiticides, incl. scabicides
CHEBI has role	CHEBI:35442	antiparasitic agent

Related Drugs by ATC class:

P03AX Other ectoparasiticides, incl. scabicides 4 drugs

benzyl alcoholbenzyl benzoatedimethiconemalathion

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pediculosis capitis	indication	81000006	DOID:5501

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.74%	XEGLYZE	LNHC	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	7812163	Oct. 28, 2026	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74%	XEGLYZE	LNHC	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	10292389	Dec. 17, 2034	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
C-C chemokine receptor type 5	GPCR	P51681	CCR5_HUMAN		EC50	5.64		CHEMBL
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN		IC50	5.99		CHEMBL
C-C chemokine receptor type 1	GPCR	P32246	CCR1_HUMAN		EC50	4.80		CHEMBL
C-C chemokine receptor type 8	GPCR	P51685	CCR8_HUMAN		EC50	5.12		CHEMBL

External reference:

ID	Source
D10687	KEGG_DRUG
6UO390AMFB	UNII
C4519258	UMLSCUI
CHEBI:192617	CHEBI
CHEMBL2205807	ChEMBL_ID
15664	PUBCHEM_CID
DB11932	DRUGBANK_ID
9829	INN_ID
926368006	SNOMEDCT_US
926389002	SNOMEDCT_US
EI3	PDB_CHEM_ID
38681	MMSL
018457	NDDF
2475532	RXNORM
6UO390AMFB	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xeglyze	HUMAN PRESCRIPTION DRUG LABEL	1	43598-921	LOTION	0.74 g	TOPICAL	NDA	25 sections